Posts

Showing posts from May, 2018

Antibody Drug Conjugates - A Groundbreaking Solution to Cancer

Image
In pursuit of more targeted therapies and clinically effective drugs, pharmaceutical companies are increasing their research and development activities in biologics. Although a majority of this work is focused on monoclonal antibodies (mAbs) and recombinant proteins, progress is being made in specialized drugs. Antibody drug conjugates (ADCs) are a new class of drugs that is gaining attention from both large and small pharmaceutical companies as they offer promise in cancer therapeutics. They consist of an mAb - an antibody that is specific to the target associated antigen, a cytotoxic drug - designed to kill target cancer cells, and a linker - that attaches the cytotoxic agent to the antibody. Thus, antibody drug conjugates combine the targeting ability of monoclonal antibody and the target specific cell killing ability of cytotoxic drugs.


The market for antibody drug conjugates is witnessing a fast growth, which is supported by the advancement in medical technology, the rise in the o…